Disease progression in recurrent glioblastoma patients treated with the VEGFR inhibitor axitinib is associated with increased regulatory T cell numbers and T cell exhaustion

Cancer Immunology, Immunotherapy

Volumn 65, Issue 6, 2016, Pages 727-740

  Du Four, Stephanie ^a   Maenhout, Sarah K ^a   Benteyn, Daphné ^a   De Keersmaecker, Brenda ^a   Duerinck, Johnny ^b   Thielemans, Kris ^a   Neyns, Bart ^b   Aerts, Joeri L ^a  

^a VRIJE UNIVERSITEIT BRUSSEL   (Belgium)

^b UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

Author keywords

Antiangiogenesis; Axitinib; Glioblastoma; Inhibitory molecules; Regulatory T cells

Indexed keywords

AXITINIB; CD11B ANTIGEN; CD15 ANTIGEN; CD4 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; GLYCOPROTEIN P 15095; HLA DR ANTIGEN; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; L SELECTIN; LOMUSTINE; LYMPHOCYTE ACTIVATION GENE 3 PROTEIN; LYMPHOCYTE ANTIGEN; T CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN 3; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANGIOGENESIS INHIBITOR; BIOLOGICAL MARKER; CD223 ANTIGEN; CYTOKINE; HAVCR2 PROTEIN, HUMAN; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; IMIDAZOLE DERIVATIVE; INDAZOLE DERIVATIVE; LEUKOCYTE ANTIGEN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITOR; VASCULOTROPIN RECEPTOR;

ADULT; AGED; ARTICLE; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; ELEVATED BLOOD PRESSURE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN CELL; IMMUNOPHENOTYPING; IN VITRO STUDY; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MEMORY T LYMPHOCYTE; MULTICENTER STUDY; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; UPREGULATION; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE; TUMOR RECURRENCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIGENS, CD; BIOMARKERS; CELL LINE, TUMOR; CYTOKINES; DISEASE PROGRESSION; FEMALE; GLIOBLASTOMA; HEPATITIS A VIRUS CELLULAR RECEPTOR 2; HUMANS; IMIDAZOLES; IMMUNOLOGIC MEMORY; IMMUNOMODULATION; IMMUNOPHENOTYPING; INDAZOLES; LYMPHOCYTE COUNT; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 84964355540     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-016-1836-3     Document Type: Article

References (36)

1. Stupp R, Mason WP, van den Bent MJ et al (2005) Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987–996
2. Lamborn KR, Chang SM, Prados MD (2004) Prognostic factors for survival of patients with glioblastoma: recursive partitioning analysis. Neuro Oncol 6:227–235
3. Friedman HS, Prados MD, Wen PY et al (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27:4733–4740
4. Stupp R, Hegi ME, Gorlia T et al (2014) Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 15:1100–1108
5. Hutterer M, Nowosielski M, Haybaeck J et al (2014) A single-arm phase II Austrian/German multicenter trial on continuous daily sunitinib in primary glioblastoma at first recurrence (SURGE 01-07). Neuro Oncol 16:92–102
6. Lee EQ, Kuhn J, Lamborn KR et al (2012) Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol 14:1511–1518
7. Batchelor TT, Mulholland P, Neyns B et al (2013) Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. J Clin Oncol 31:3212–3218
8. Neyns B, Duerinck J, Du Four S et al (2014) Randomized phase II study of axitinib versus standard of care in patients with recurrent glioblastoma. ASCO Meet Abstr 32:2018
9. Duerinck J, Du Four S, Bouttens F, Neyns B (2016) Randomized phase II study of axitinib versus physicians best alternative choice of therapy in patients with recurrent glioblastoma. J Neurooncol. doi:10.1007/s11060-016-2092-2
10. Taal W, Oosterkamp HM, Walenkamp AME et al (2014) Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. Lancet Oncol 15:943–953
11. Huang Y, Goel S, Duda DG et al (2013) Vascular normalization as an emerging strategy to enhance cancer immunotherapy. Cancer Res 73:2943–2948
12. Du Four S, Maenhout SK, De Pierre K et al (2015) Axitinib increases the infiltration of immune cells and reduces the suppressive capacity of monocytic MDSCs in an intracranial mouse melanoma model. Oncoimmunology 4:e998107. doi:10.1080/2162402X.2014.998107
13. Jackson CM, Lim M, Drake CG (2014) Immunotherapy for brain cancer: recent progress and future promise. Clin Cancer Res 20:3651–3659. doi:10.1158/1078-0432.CCR-13-2057
14. Reardon DA, Schuster J, Tran DD et al (2015) ReACT: overall survival from a randomized phase II study of rindopepimut (CDX-110) plus bevacizumab in relapsed glioblastoma. ASCO Meet Abstr 33:2009
15. Chung AS, Wu X, Zhuang G et al (2013) An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat Med 19:1114–1123
16. Doloff JC, Waxman DJ (2012) VEGF receptor inhibitors block the ability of metronomically dosed cyclophosphamide to activate innate immunity-induced tumor regression. Cancer Res 72:1103–1115
17. Stehle F, Schulz K, Fahldieck C et al (2013) Reduced immunosuppressive properties of axitinib in comparison with other tyrosine kinase inhibitors. J Biol Chem 288:16334–16347
18. Gattinoni L, Klebanoff CA, Palmer DC et al (2005) Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8 + T cells. J Clin Invest 115:1616–1626
19. Klebanoff Christopher, Gattoni Luca, Restifo N (2012) Sorting through subsets: which T cell populations mediate highly effective adoptive immunotherapy? J Immunother 35:651–660
20. Fourcade J, Sun Z, Pagliano O et al (2012) CD8 + T cells specific for tumor antigens can be rendered dysfunctional by the tumor microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. Cancer Res 72:887–896
21. Fourcade J, Sun Z, Pagliano O et al (2014) PD-1 and Tim-3 regulate the expansion of tumor antigen-specific CD8 + T cells induced by melanoma vaccines. Cancer Res 74:1045–1055
22. Clary S, Nagarkatti PS, Nagarkatti M (1990) Immunomodulatory effects of nitrosoureas on the phenotype and functions of T cells in the thymus and periphery. Immunopharmacology 20:153–164
23. Nguyen LT, Ohashi PS (2015) Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat Rev Immunol 15:45–56. doi:10.1038/nri3790
24. Goldberg MV, Drake CG (2011) LAG-3 in cancer immunotherapy. Curr Top Microbiol Immunol 344:269–278
25. Wei B, Wang L, Zhao X et al (2014) The upregulation of programmed death 1 on peripheral blood T cells of glioma is correlated with disease progression. Tumor Biol 35:2923–2929
26. Ozao-Choy J, Ma G, Kao J et al (2009) The novel role of Tyrosine Kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res 69:2514–2522
27. Chen ML, Yan BS, Lu WC et al (2014) Sorafenib relieves cell-intrinsic and cell-extrinsic inhibitions of effector T cells in tumor microenvironment to augment antitumor immunity. Int J Cancer 134:319–331
28. Guislain A, Gadiot J, Kaiser A et al (2015) Sunitinib pretreatment improves tumor—infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid—derived suppressor cells in human renal cell carcinoma. Cancer Immunol Immunother 64:1241–1250
29. Curiel TJ, Coukos G, Zou L et al (2004) Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10:942–949
30. Choi BD, Fecci PE, Sampson JH (2012) Regulatory T cells move in when gliomas say “I DO”. Clin Cancer Res 18:6086–6088
31. Fecci PE, Mitchell DA, Whitesides JF et al (2006) Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res 66:3294–3302
32. Thomas AA, Fisher JL, Rahme GJ et al (2015) Regulatory T cells are not a strong predictor of survival for patients with glioblastoma. Neuro Oncol 17:801–809
33. Wainwright DA, Chang AL, Dey M et al (2014) Durable therapeutic efficacy utilizing combinatorial blockade against IDO, CTLA-4, and PD-L1 in mice with brain tumors. Clin Cancer Res 20:5290–5301
34. Motz GT, Santoro SP, Wang L-P et al (2014) Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med 20:607–615
35. Batchelor TT, Reardon DA, de Groot JF et al (2014) Antiangiogenic therapy for glioblastoma: current status and future prospects. Clin Cancer Res 20:5612–5619
36. Franchimont D (2004) Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci 1024:124–137